| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
| Targets |
Magnoloside A targets calcineurin (calmodulin phosphatase), a calcium/calmodulin-dependent protein phosphatase that plays a critical role in T-cell activation and various cellular processes. By inhibiting calcineurin, the compound modulates immune responses and may contribute to its anti-inflammatory effects. Additionally, Magnoloside A exhibits potent antifungal activity against Cryptococcus neoformans and related strains, suggesting that it may target fungal-specific pathways such as the calcineurin-Hog1 signaling axis. The compound also shows immunomodulatory effects.
|
|---|---|
| ln Vitro |
In cell-free and cellular assays, Magnoloside A demonstrates potent antifungal activity against various Cryptococcus strains with minimum inhibitory concentration (MIC) values ranging from 1.0 to 4.0 μg/mL. Against Cryptococcus neoformans, the MIC is reported as 0.5 mg/mL. The compound shows no cytotoxic effects on human cells at concentrations up to 2 mg/mL, indicating a favorable selectivity index for antifungal activity. As a calcineurin inhibitor, it acts specifically on the calcineurin pathway of C. neoformans, which is essential for fungal virulence and stress responses.
|
| ln Vivo |
Specific in vivo data for Magnoloside A are limited. However, given its potent antifungal activity and oral bioavailability, the compound has potential for in vivo efficacy studies in animal models of cryptococcal infection. Such studies would involve administration of Magnoloside A to infected mice, followed by assessment of fungal burden in tissues, survival rates, and histopathological analysis. The compound's calcineurin inhibitory activity also suggests potential applications in immunosuppression or anti-inflammatory models. Magnoloside A has been studied for functional dyspepsia (FD).
|
| Enzyme Assay |
The antifungal activity is assessed using broth microdilution assays following Clinical and Laboratory Standards Institute (CLSI) guidelines. Various Cryptococcus strains are cultured in appropriate media and incubated with serial dilutions of Magnoloside A. The MIC is defined as the lowest concentration that inhibits visible fungal growth after 48-72 hours of incubation at 35°C. To determine the mechanism of action, a two-component screening system using both wild-type C. neoformans and a calcineurin mutant is employed. Cytotoxicity is assessed in human cell lines using standard viability assays.
|
| Cell Assay |
Cellular assays are performed to evaluate antifungal activity and cytotoxicity. For antifungal testing, C. neoformans and other Cryptococcus strains are cultured in yeast extract-peptone-dextrose (YPD) medium. Cells are treated with Magnoloside A at various concentrations, and growth inhibition is measured by optical density at 600 nm or by colony counting on agar plates. For cytotoxicity assessment, human cell lines (e.g., HEK293, HepG2) are treated with Magnoloside A at concentrations up to 2 mg/mL, and cell viability is measured using MTT or similar assays.
|
| Animal Protocol |
In vivo studies for Magnoloside A would be conducted in mouse models of cryptococcal infection. Mice would be infected intranasally or intravenously with C. neoformans, followed by oral or intraperitoneal administration of Magnoloside A at various doses. Treatment efficacy would be assessed by measuring survival rates, fungal burden in brain and lung tissues, and histopathological examination of affected organs. For functional dyspepsia research, appropriate rodent models would be used to evaluate gastrointestinal function and symptom relief.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Magnoloside A are not extensively reported. However, the compound is described as orally available, suggesting reasonable oral absorption and systemic exposure. As a glycoside with molecular weight 624.59 g/mol, its bioavailability may be influenced by intestinal metabolism and efflux transport. Pharmacokinetic studies would be needed to determine parameters such as Cmax, Tmax, half-life, and oral bioavailability in animal models. The compound's stability in biological matrices and protein binding properties would also require characterization.
|
| Toxicity/Toxicokinetics |
Toxicological data for Magnoloside A are limited but encouraging. The compound shows no cytotoxic effects on human cells at concentrations up to 2 mg/mL, indicating a favorable safety profile. As a natural product from Magnolia obovata, which has traditional medicinal use, the compound is generally considered to have moderate safety. However, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. Standard safety evaluations would be required before any clinical development.
|
| References | |
| Additional Infomation |
Reports indicate that [(2R,3R,4R,5R,6R)-2-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxacyclohexane-2-yl]oxacyclohexane-4-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid ester exists in Magnolia obovata, and related data are available.
Magnoloside A is a phenylethanol glycoside from Magnolia obovata that acts as a selective calcineurin inhibitor and potent antifungal agent. It exhibits MIC values of 1.0-4.0 μg/mL against Cryptococcus strains and no cytotoxicity in human cells up to 2 mg/mL. The compound has been studied for functional dyspepsia and cryptococcal meningitis. No clinical trials or regulatory approvals have been reported. All information is for research use only. |
| Molecular Formula |
C29H36O15
|
|---|---|
| Molecular Weight |
624.58700
|
| Exact Mass |
624.205
|
| CAS # |
113557-95-2
|
| PubChem CID |
21629882
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
908.8±65.0 °C at 760 mmHg
|
| Flash Point |
294.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.689
|
| LogP |
2.61
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
44
|
| Complexity |
936
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@@H]([C@@H]([C@@H](CO)O[C@H]2OCCC3=CC(=C(C=C3)O)O)O)OC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O
|
| InChi Key |
QLZWUGOYBODRLF-QQLYGORSSA-N
|
| InChi Code |
InChI=1S/C29H36O15/c1-13-22(36)24(38)25(39)28(41-13)44-27-26(43-21(35)7-4-14-2-5-16(31)18(33)10-14)23(37)20(12-30)42-29(27)40-9-8-15-3-6-17(32)19(34)11-15/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28-,29+/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-2-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-4-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL | |
| 5 mM | 0.3202 mL | 1.6011 mL | 3.2021 mL | |
| 10 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
